Synapse - Long-term sustained minimal residual disease (MRD) negativity in patients with multiple myeloma treated with continuous lenalidomide maintenance therapy: A clinical and correlative phase 2 study

Long-term sustained minimal residual disease (MRD) negativity in patients with multiple myeloma treated with continuous lenalidomide maintenance therapy: A clinical and correlative phase 2 study Meeting Abstract

Authors:	Diamond, B.; Korde, N.; Lesokhin, A. M.; Smith, E. L.; Shah, U. A.; Mailankody, S.; Hultcrantz, M.; Hassoun, H.; Lu, S. X.; Tan, C.; Massey, D.; Salcedo, M.; Diab, V.; Werner, K.; Rispoli, J.; Sams, A.; Verducci, D.; Jones, K.; Schlossman, J.; Chansakul, A.; Harrison, A.; Ciardiello, A. K.; Tavitian, E.; Shekarkhand, T.; Piacentini, C.; Rustad, E. H.; Yellapantula, V. D.; Maura, F.; Peterson, T. J.; Derkach, A.; Devlin, S.; Landau, H. J.; Scordo, M.; Chung, D. J.; Shah, G. L.; Lahoud, O. B.; Thoren, K.; Murata, K.; Ramanathan, L.; Arcila, M. E.; Ho, C.; Roshal, M.; Dogan, A.; Giralt, S. A.; Landgren, O.
Abstract Title:	Long-term sustained minimal residual disease (MRD) negativity in patients with multiple myeloma treated with continuous lenalidomide maintenance therapy: A clinical and correlative phase 2 study
Meeting Title:	62nd Annual Meeting of the American Society of Hematology (ASH)
Journal Title:	Blood
Volume:	136
Issue:	Suppl. 1
Meeting Dates:	2020 Dec 5-8
Meeting Location:	Virtual
ISSN:	0006-4971
Publisher:	American Society of Hematology
Date Published:	2020-11-05
Language:	English
ACCESSION:	WOS:000607547202190
DOI:	10.1182/blood-2020-140152
PROVIDER:	wos
Notes:	Meeting Abstract: 18 -- MSK author Donna Mastey's last name is misspelled on the original publication -- Source: Wos